bunazosin has been researched along with Hypertension in 34 studies
bunazosin: structure
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effect of a slow-release alpha1-receptor blocker, bunazosin hydrochloride, on leptin levels and insulin resistance in obese hypertensive patients with hyperleptinemia." | 9.12 | An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. ( Ihara, S; Kawana, M; Sakai, R; Shimamoto, K; Watanabe, H, 2006) |
| "In conclusions, in mild/moderate arterial hypertension, bunazosin in monotherapy at the dosage of 3-6 mg/day, is an effective and safe treatment." | 9.07 | [Dose-response study of bunazosin in the treatment of light-to-moderate arterial hypertension]. ( De Luca, N; Fontana, D; Lamenza, F; Marchegiano, R; Sarno, D; Tozzi, N, 1993) |
| "In a randomised, placebo-controlled design 40 patients with moderately severe essential hypertension were treated with bunazosin (CAS 52712-76-2) retard in increasing doses ranging between 6 and 18 mg/day." | 9.07 | [Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study]. ( Kirsten, R; Weidinger, G, 1994) |
| "The effects of bunazosin and propranolol administration on hypertension and serum levels of lipids, lipoproteins and apolipoproteins were studied in a controlled, randomized multicenter study." | 9.06 | Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essential hypertension. ( Arakawa, K; Koga, S; Sasaki, J; Uzawa, H, 1989) |
| "To assess the protective effect of an alpha 1-blocker on the development of cardiac hypertrophy, the selective alpha 1-receptor antagonist bunazosin (2 mg/kg/d, by oral gavage and in drinking water) was given to male Dahl salt-sensitive rats fed a 4% NaCl diet for 7 weeks." | 7.69 | Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the alpha 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats. ( Fukuda, N; Izumi, Y; Kanmatsuse, K; Kubo, A; Matsuoka, M; Nakayama, T; Soma, M; Watanabe, Y, 1996) |
| "To investigate insulin insensitivity and its reversibility, we performed an insulin sensitivity test using the steady state plasma glucose (SSPG) method in 10 lean hypertensive subjects with normal glucose tolerance before and after treatment with alpha 1-blocker bunazosin, and 14 age body mass index-adjusted healthy control subjects." | 7.68 | Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin). ( Asakura, Y; Harano, Y; Hirose, J; Kageyama, A; Omae, T; Sato, A; Suzuki, M, 1992) |
| "The renal and hormonal effects of the alpha 1-adrenoceptor blocker bunazosin were examined in 6 patients with essential hypertension." | 7.67 | Renal and hormonal effects of alpha 1-adrenoceptor blockade by bunazosin in essential hypertension. ( Dan, Y; Fukui, K; Hirata, Y; Ishii, M; Matsuoka, H; Sugimoto, T, 1989) |
| "Oral bunazosin hydrochloride, a new alpha 1-blocker, for 12 weeks was given to ten outpatients diagnosed as having essential hypertension associated with hypercholesterolemia." | 7.67 | Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia. ( Kuroiwa, A; Nakashima, Y; Sugano, M; Tasaki, H; Yashiro, A, 1987) |
| "Bunazosin was shown to decrease the systolic and diastolic blood pressure without a reflex tachycardia." | 6.39 | Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ( Weidinger, G, 1995) |
| " We investigated the effect of a slow-release alpha1-receptor blocker, bunazosin hydrochloride, on leptin levels and insulin resistance in obese hypertensive patients with hyperleptinemia." | 5.12 | An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. ( Ihara, S; Kawana, M; Sakai, R; Shimamoto, K; Watanabe, H, 2006) |
| "This was a double-blind randomized study comparing the efficacy of two alpha 1-antagonists, bunazosin retard and prazosin retard, in 185 patients with mild to moderate essential hypertension." | 5.08 | Orthostatic hypotension: how to avoid it during antihypertensive therapy. ( Rieckert, H, 1996) |
| "To compare the effects of the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol (Uniloc) on insulin sensitivity and glucose and lipid homeostasis in patients with type-2 diabetes and hypertension." | 5.08 | Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients. ( Eriksson, JW; Foley, K; Jansson, PA; Lithell, H, 1996) |
| "In conclusions, in mild/moderate arterial hypertension, bunazosin in monotherapy at the dosage of 3-6 mg/day, is an effective and safe treatment." | 5.07 | [Dose-response study of bunazosin in the treatment of light-to-moderate arterial hypertension]. ( De Luca, N; Fontana, D; Lamenza, F; Marchegiano, R; Sarno, D; Tozzi, N, 1993) |
| "In a randomised, placebo-controlled design 40 patients with moderately severe essential hypertension were treated with bunazosin (CAS 52712-76-2) retard in increasing doses ranging between 6 and 18 mg/day." | 5.07 | [Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study]. ( Kirsten, R; Weidinger, G, 1994) |
| "The effects of bunazosin and propranolol administration on hypertension and serum levels of lipids, lipoproteins and apolipoproteins were studied in a controlled, randomized multicenter study." | 5.06 | Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essential hypertension. ( Arakawa, K; Koga, S; Sasaki, J; Uzawa, H, 1989) |
| " In our patient, both YM-09538 and bunazosin were effective in controlling severe hypertension preoperatively." | 4.77 | Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature. ( Ohno, M; Oishi, S; Sasaki, M; Sato, T; Umeda, T, 1988) |
| "To assess the protective effect of an alpha 1-blocker on the development of cardiac hypertrophy, the selective alpha 1-receptor antagonist bunazosin (2 mg/kg/d, by oral gavage and in drinking water) was given to male Dahl salt-sensitive rats fed a 4% NaCl diet for 7 weeks." | 3.69 | Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the alpha 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats. ( Fukuda, N; Izumi, Y; Kanmatsuse, K; Kubo, A; Matsuoka, M; Nakayama, T; Soma, M; Watanabe, Y, 1996) |
| "To investigate insulin insensitivity and its reversibility, we performed an insulin sensitivity test using the steady state plasma glucose (SSPG) method in 10 lean hypertensive subjects with normal glucose tolerance before and after treatment with alpha 1-blocker bunazosin, and 14 age body mass index-adjusted healthy control subjects." | 3.68 | Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin). ( Asakura, Y; Harano, Y; Hirose, J; Kageyama, A; Omae, T; Sato, A; Suzuki, M, 1992) |
| "The renal and hormonal effects of the alpha 1-adrenoceptor blocker bunazosin were examined in 6 patients with essential hypertension." | 3.67 | Renal and hormonal effects of alpha 1-adrenoceptor blockade by bunazosin in essential hypertension. ( Dan, Y; Fukui, K; Hirata, Y; Ishii, M; Matsuoka, H; Sugimoto, T, 1989) |
| "Oral bunazosin hydrochloride, a new alpha 1-blocker, for 12 weeks was given to ten outpatients diagnosed as having essential hypertension associated with hypercholesterolemia." | 3.67 | Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia. ( Kuroiwa, A; Nakashima, Y; Sugano, M; Tasaki, H; Yashiro, A, 1987) |
| "Bunazosin, however, was far better tolerated with 43." | 2.68 | Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double-blind randomized controlled study. ( Assmann, I; Bräutigam, M; Krönig, B; Langenfeld, MR; Schmieder, RE; Weidinger, G, 1996) |
| " There were, however, neither prolongation of apparent elimination half-life (t1/2), nor increase in Cmax, nor area under the plasma concentration-time curve (AUC0-24) after consecutive dosing in both groups." | 2.67 | Pharmacokinetics and pharmacodynamics of the alpha 1-adrenergic antagonist bunazosin retard in hypertensives. ( Gotoh, E; Ishii, M; Minamisawa, K; Minamisawa, M; Shionoiri, H; Sugimoto, K; Takasaki, I; Takizawa, T; Ueda, S, 1994) |
| "Bunazosin Retard was associated with increases in GFR and ERPF in both normal and renally impaired groups; the increases were statistically significant in the renally impaired group (n = 14)." | 2.67 | Renal haemodynamic effects of bunazosin retard and prazosin in mild to moderately hypertensive patients with normal or moderately impaired renal function. ( Anderton, JL; Gill, M; Notghi, A, 1994) |
| "Bunazosin was shown to decrease the systolic and diastolic blood pressure without a reflex tachycardia." | 2.39 | Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review. ( Weidinger, G, 1995) |
| "Bunazosin hydrochloride was given orally in a dose of 10 mg." | 1.28 | Effects of long term treatment with an alpha 1 adrenoceptor blocker on cardiac hypertrophy, contractility, and myosin isoenzymes in spontaneously hypertensive rats. ( Iwai, T; Nagano, M; Nakamura, I; Ohkubo, T; Takeda, N; Tanamura, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (29.41) | 18.7374 |
| 1990's | 23 (67.65) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ihara, S | 1 |
| Shimamoto, K | 1 |
| Watanabe, H | 2 |
| Sakai, R | 1 |
| Kawana, M | 1 |
| Shionoiri, H | 1 |
| Minamisawa, M | 1 |
| Ueda, S | 1 |
| Minamisawa, K | 1 |
| Takizawa, T | 1 |
| Takasaki, I | 1 |
| Sugimoto, K | 1 |
| Gotoh, E | 1 |
| Ishii, M | 2 |
| Marchegiano, R | 1 |
| Lamenza, F | 1 |
| Sarno, D | 1 |
| Tozzi, N | 1 |
| Fontana, D | 1 |
| De Luca, N | 1 |
| Kirsten, R | 1 |
| Weidinger, G | 5 |
| Harder, S | 1 |
| Thürmann, P | 1 |
| Anderton, JL | 1 |
| Gill, M | 1 |
| Notghi, A | 1 |
| Nishimura, H | 1 |
| Kubota, J | 1 |
| Okabe, M | 1 |
| Ueyama, M | 1 |
| Oka, T | 1 |
| Kawamura, K | 1 |
| Izumi, Y | 1 |
| Matsuoka, M | 1 |
| Kubo, A | 1 |
| Nakayama, T | 1 |
| Fukuda, N | 1 |
| Watanabe, Y | 1 |
| Soma, M | 1 |
| Kanmatsuse, K | 1 |
| Schobel, HP | 1 |
| Langenfeld, M | 1 |
| Gatzka, C | 1 |
| Schmieder, RE | 2 |
| Rieckert, H | 1 |
| Schmitz, G | 1 |
| Stumpe, KO | 1 |
| Herrmann, W | 1 |
| Eriksson, JW | 1 |
| Jansson, PA | 1 |
| Foley, K | 1 |
| Lithell, H | 1 |
| Bönner, G | 1 |
| Schmieder, R | 1 |
| Chrosch, R | 1 |
| Langenfeld, MR | 1 |
| Bräutigam, M | 1 |
| Assmann, I | 1 |
| Krönig, B | 1 |
| Suzuki, H | 1 |
| Meyer, U | 1 |
| Schmidt, J | 1 |
| Tada, Y | 1 |
| Tsuda, Y | 1 |
| Otsuka, T | 1 |
| Nagasawa, K | 1 |
| Kimura, H | 1 |
| Kusaba, T | 1 |
| Sakata, T | 1 |
| Koshiji, M | 1 |
| Ito, H | 1 |
| Minatoguchi, S | 1 |
| Imai, Y | 1 |
| Kakami, M | 1 |
| Hirakawa, S | 1 |
| Suzuki, M | 1 |
| Hirose, J | 1 |
| Asakura, Y | 1 |
| Sato, A | 1 |
| Kageyama, A | 1 |
| Harano, Y | 1 |
| Omae, T | 1 |
| Takeda, N | 1 |
| Nakamura, I | 1 |
| Ohkubo, T | 1 |
| Iwai, T | 1 |
| Tanamura, A | 1 |
| Nagano, M | 1 |
| Kuriyama, S | 1 |
| Nakamura, K | 1 |
| Kaguchi, Y | 1 |
| Tomonari, H | 1 |
| Tokutome, G | 1 |
| Hashimoto, T | 1 |
| Sakai, O | 1 |
| Baba, T | 1 |
| Tomiyama, T | 1 |
| Murabayashi, S | 1 |
| Takebe, K | 1 |
| Hirata, Y | 1 |
| Fukui, K | 1 |
| Dan, Y | 1 |
| Matsuoka, H | 1 |
| Sugimoto, T | 1 |
| Takada, S | 1 |
| Uehara, Y | 1 |
| Hirawa, N | 1 |
| Numabe, A | 1 |
| Yagi, S | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Sasaki, J | 1 |
| Koga, S | 1 |
| Uzawa, H | 1 |
| Arakawa, K | 1 |
| Nakai, M | 1 |
| Yamamoto, J | 1 |
| Matsui, Y | 1 |
| Yashiro, A | 1 |
| Sugano, M | 1 |
| Nakashima, Y | 1 |
| Tasaki, H | 1 |
| Kuroiwa, A | 1 |
| Sone, T | 1 |
| Tanaka, S | 1 |
| Tsukahara, I | 1 |
| Harada, T | 1 |
| Iida, H | 1 |
| Tanahashi, T | 1 |
| Oishi, S | 1 |
| Sasaki, M | 1 |
| Ohno, M | 1 |
| Umeda, T | 1 |
| Sato, T | 1 |
| Chiba, S | 1 |
| Tsukada, M | 1 |
| Katsuyama, Y | 1 |
| Tada, A | 1 |
| Zenda, H | 1 |
| Minami, M | 1 |
| Togashi, H | 1 |
| Sano, M | 1 |
| Yoshioka, M | 1 |
| Saito, I | 1 |
| Morii, K | 1 |
| Tochihara, M | 1 |
| Hirogami, M | 1 |
| Nomura, A | 1 |
| Saito, H | 1 |
3 reviews available for bunazosin and Hypertension
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. A review.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Humans; Hypertension | 1995 |
Treatment of benign prostatic hyperplasia and hypertension in elderly hypertensive patients.
Topics: Adrenergic alpha-Antagonists; Aged; Female; Humans; Hypertension; Male; Multicenter Studies as Topic | 1998 |
Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Blood Pressure; Catecholamines; Ethanolamines; Hum | 1988 |
14 trials available for bunazosin and Hypertension
| Article | Year |
|---|---|
An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; | 2006 |
Pharmacokinetics and pharmacodynamics of the alpha 1-adrenergic antagonist bunazosin retard in hypertensives.
Topics: Adrenergic alpha-1 Receptor Antagonists; Blood Pressure; Delayed-Action Preparations; Female; Half-L | 1994 |
[Dose-response study of bunazosin in the treatment of light-to-moderate arterial hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Dose-Response Relationship, Drug; Drug Evaluation; Female; Huma | 1993 |
[Treatment of essential hypertension with the alpha-1 antagonist bunazosin retard. A multicenter, double-blind, placebo-controlled study].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Blood Pressure; Delayed-Actio | 1994 |
Concentration/effect relationship of bunazosin, a selective alpha 1-adrenoceptor antagonist in hypertensive patients after single and multiple oral doses.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Delayed-Action Prep | 1994 |
Renal haemodynamic effects of bunazosin retard and prazosin in mild to moderately hypertensive patients with normal or moderately impaired renal function.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Blood Pressure; Female; Glomerular Filtration | 1994 |
Treatment and post-treatment effects of alpha- versus beta-receptor blockers on left ventricular structure and function in essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Double-Blind Method; Female; Heart | 1996 |
Orthostatic hypotension: how to avoid it during antihypertensive therapy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressur | 1996 |
Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial.
Topics: Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Apolipoproteins; Atenolol; Double-Blin | 1996 |
Insulin sensitivity following treatment with the alpha 1-blocker bunazosin retard and the beta 1-blocker atenolol in hypertensive non-insulin-dependent diabetes mellitus patients.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Glucose; Blo | 1996 |
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Antihypertensive efficacy and orthostatic tolerance of bunazosin vs nitrendipine: a multicentre double-blind randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Double-Blind Method; Humans; Hypertension; Lo | 1996 |
Renal effects of bunazosin, a new alpha 1-adrenoceptor blocker, in patients with mild-to-moderate essential hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Blood Pressure; Female; Glomerular Filtration Rate; Hemodynamic | 1990 |
Comparative effects of bunazosin and propranolol on serum lipids and apolipoproteins in patients with essential hypertension.
Topics: Apolipoproteins; Blood Pressure; Female; Humans; Hypertension; Lipids; Lipoproteins; Male; Middle Ag | 1989 |
17 other studies available for bunazosin and Hypertension
| Article | Year |
|---|---|
Long-term alpha 1 blockade does not reverse cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Ma | 1993 |
Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the alpha 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cardiomegaly; Hypertension; Male; Quinazoline | 1996 |
[Alpha-1 blockers for therapy of essential hypertension. 2 clinical studies with bunazosin].
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration | 1998 |
Bunazosin. Andante, Detantol, E 1015, E 643, EA 0643.
Topics: Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Area Under Curve; Clinical Trials as To | 1999 |
Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Drug Interactions; Ethambutol; Female; Humans; H | 1992 |
A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Atenolol; Blood Pressure; Cold Temperature; G | 1992 |
Insulin insensitivity in nonobese, nondiabetic essential hypertension and its improvement by an alpha 1-blocker (bunazosin).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Apoproteins; Blood Glucose; Blood Pressure; Catecholamine | 1992 |
Effects of long term treatment with an alpha 1 adrenoceptor blocker on cardiac hypertrophy, contractility, and myosin isoenzymes in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Heart; Hypertension; Male; Myocardial Contrac | 1991 |
Differential effects of antihypertensive agents on proliferation of vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Cell Division; Cells, Cultured; Hypertension; Male; Muscle, S | 1991 |
Renal and hormonal effects of alpha 1-adrenoceptor blockade by bunazosin in essential hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Atrial Natriuretic Factor; Blood Pressure | 1989 |
[Roles of vascular and renal thromboxanes in the antihypertensive effects of alpha 1 adrenoceptor antagonists].
Topics: Adrenergic alpha-Antagonists; Animals; Blood Vessels; Hypertension; Kidney; Male; Methacrylates; Qui | 1989 |
[Clinical application of adrenoceptor blockers in the treatment of hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 1989 |
Acute systemic and regional hemodynamic effects of alpha 1-adrenoceptor blockade in conscious spontaneously hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Animals; Consciousness; Dose-Response Relationship, Drug; Hemodynamics | 1986 |
Effects of a new alpha 1-blocker, bunazosin hydrochloride, on plasma lipid components in hypertensive patients with hypercholesterolemia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apolipoproteins; Blood Pressure; Cholesterol; | 1987 |
[The effect of bunazosin on hypertension during anesthesia; effectiveness of nasal instillation].
Topics: Administration, Intranasal; Adrenergic alpha-Antagonists; Anesthesia, General; Female; Humans; Hyper | 1988 |
Vasoconstrictor effects of endogenous digitalis-like factors extracted from urine of hypertensive patients.
Topics: Animals; Arteries; Blood Proteins; Cardenolides; Digoxin; Dogs; Ear, External; Epinephrine; Humans; | 1987 |
[Effects of new antihypertensive agent, 2-[4-(n-butyryl)-homopiperazine-1-ul]-4-amino-6, 7-dimethoxy-quinazoline (E-643), on blood pressure, urinary sodium excretion and urinary norepinephrine excretion rate in stroke-prone, spontaneously hypertensive rat
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Catecholamines; Cerebrovascular Disor | 1985 |